title: Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
abstract: OBJECTIVE
  To explore in the daily clinical practice setting that antimuscarinic, Fesoterodine or Solifenacin, provides a greater clinical benefit after changing their prior Overactive Bladder (OAB) therapy with tolterodine extended-release (ER) to other novel antimuscarinic agents.
  
  
  METHODS
  A post-hoc analysis of data from an observational multicenter, cross-sectional, retrospective study. Adult patients of both sexes, with OAB and OAB-V8 score≥8, who switched to fesoterodine or solifenacin within the 3-4 months before study visit from their prior tolterodine-ER-based therapy due to poor response were included. 92 patients were selected for each treatment group, matched (1:1) according to conditioned probability using the propensity score. Benefit of treatment change perceived by the physician and patient was evaluated by means of the Clinical Global Impression of Improvement subscale (CGI-I) and Treatment Benefit Scale (TBS), respectively. Degree of worry, bother and interference with daily living activities due to urinary symptoms, level of satisfaction, and preference for current treatment were also assessed.
  
  
  RESULTS
  Fesoterodine provided a significantly greater improvement than solifenacina in terms of therapeutic benefit perceived by the physician according to ICG-I. 96.7% of the patients on fesoterodine treatment vs. 81.6% of the solifenacin group showed a score of improvement in TBS (P<.05). Fesoterodine was also better rated than solifenacin with regard to satisfaction and preference for the new treatment (93.4 vs. 78.2% P<.05).
  
  
  CONCLUSIONS
  In daily clinical practice the switch from tolterodine LP to fesoterodine seems to provide greater benefits both from the physician's and the patient's point of view compared with those provided by solifenacin.
authors.affiliation: Departamento de Urología, Hospital General Universitario de Valencia, Valencia, España.
authors.forename: F
authors.initials: F
authors.lastname: Sánchez-Ballester
authors.affiliation: Departamento de Ginecología, Hospital de Fuenlabrada, Madrid, España.
authors.forename: P
authors.initials: P
authors.lastname: Miranda
authors.affiliation: Unidad Médica, Pfizer, S.L.U., Alcobendas, Madrid, España. Electronic address: isabel.lizarraga@pfizer.com.
authors.forename: I
authors.initials: I
authors.lastname: Lizarraga
authors.affiliation: Departamento de Investigación de Resultados en Salud y Farmacoeconomía, Pfizer, S.L.U., Alcobendas, Madrid, España.
authors.forename: J
authors.initials: J
authors.lastname: Rejas
authors.affiliation: Departamento Médico, Pfizer Europe, Alcobendas, Madrid, España.
authors.forename: D
authors.initials: D
authors.lastname: Arumi
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015897:Comorbidity; D003408:Cresols / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D057915:Drug Substitution; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D064887:Observational Studies as Topic / Q000706:statistics & numerical data; D057240:Patient Preference; D017060:Patient Satisfaction; D010549:Personal Satisfaction; D010665:Phenylpropanolamine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010820:Physicians / Q000523:psychology; D057216:Propensity Score; D011812:Quinuclidines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012189:Retrospective Studies; D018401:Sample Size; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013810:Therapeutic Equivalency; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000523:psychology; D064804:Urological Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D064804:Urological Agents; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C526675:fesoterodine; D000069464:Solifenacin Succinate
keywords: Beneficio terapéutico; Fesoterodina; Fesoterodine; Overactive bladder; Solifenacin; Solifenacina; Treatment benefit; Vejiga hiperactiva